For patients with a new lymphoma diagnosis, the initial shock and anxiety are paramount. Clinicians should first focus on establishing a trusting relationship and providing emotional reassurance, deferring detailed treatment discussions until the patient is more settled.
Simplifying complex oncology treatments like chemotherapy, ADCs, and bispecific antibodies is crucial for patient education. Analogies—such as comparing chemotherapy to "carpet bombing" a city and targeted therapies to "guided missiles"—can effectively demystify these concepts for patients and families.
Loncastuximab Tesirine (Lanka-T) can cause a unique "third spacing" side effect, leading to significant edema and fluid retention that is resistant to common diuretics like furosemide (Lasix). Spironolactone has proven more effective for managing this specific toxicity, representing a key clinical pearl for nurses and prescribers.
The photosensitivity reaction from loncastuximab tesirine can cause severe blistering. It's insufficient to only warn the patient. Clinicians must ensure that all caregivers, including family and facility staff, understand the need to keep the patient out of direct sunlight to prevent serious skin toxicity.
One of the most challenging patient conversations in oncology is explaining that a follicular lymphoma diagnosis does not require immediate treatment. Clinicians must carefully manage patient anxiety and build trust to help them accept the "watch and wait" strategy, preventing unnecessary distress.
When educating staff and patients about immunotherapies, it is helpful to distinguish between the desired effect (cytokine release killing cancer cells) and the dangerous toxicity (CRS). This reframing clarifies that CRS is an over-expression of the drug's intended mechanism, not a separate, unrelated side effect.
The neuropathy caused by polatuzumab vedotin can be severe and is not always reversible. Clinicians must be vigilant in assessing for symptoms like numbness or difficulty with fine motor skills and be prepared to reduce the dose promptly to prevent long-term, debilitating side effects.
When CLL patients temporarily stop their BTK inhibitor for a procedure, they can experience a "disease flare" mimicking relapse. It is critical for clinicians to recognize this phenomenon and not misinterpret it as true disease progression, as symptoms typically resolve upon restarting the medication.
While generally well-tolerated, the BTK inhibitor acalabrutinib is associated with headaches. This side effect is particularly pronounced and often intolerable in patients with a pre-existing history of migraines. For these patients, an alternative BTK inhibitor like zanubrutinib is a more appropriate choice.
The acute toxicity risk during the initial ramp-up phase of bispecific antibodies (like CRS and ICANS) makes them challenging to manage in a typical community oncology setting. A safer model involves academic centers managing the high-risk initiation period before transitioning the patient back to their community provider for ongoing care.
Obinutuzumab infusions in CLL patients can cause severe reactions. A simple and effective mitigation strategy is to pre-treat the patient with a BTK inhibitor for as little as three days before the first infusion. This debulking effect significantly reduces infusion reaction risk and improves patient safety.
When starting a BTK inhibitor for CLL, patients often experience a sharp increase in their lymphocyte count. This is not a sign of disease progression but a therapeutic effect as the drug forces malignant cells out of the lymph nodes. This effect typically normalizes over 6-8 weeks and should be explained to patients.